|Systematic (IUPAC) name|
|[(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide|
|Trade names||Bretaris Genuair, Eklira Genuair, Tudorza Pressair|
|Licence data||US FDA:|
|Mol. mass||564.555 g/mol|
|(what is this?)|
Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD. However, it does not appear to affect the risk of death or the frequency steroids are needed. It is unclear if it differs from the similar medication tiotropium or another commonly used medication class of LAMAs.
Aclidinium is delivered via a, multidose dry powder inhaler, the Genuair inhaler.
It is marketed under the brand name Tudorza Pressair in the US, Eklira Genuair in the UK, and Tudorza Genuair in Canada; licensed to Menarini under the brand name Bretaris Genuair for majority of EU member states
- "Forest Laboratories and Almirall Announce FDA Approval of Tudorza™ Pressair™ for the Long-Term Maintenance Treatment of COPD" (Press release). Forest Laboratories. Retrieved 2012-07-24.
- Gavaldà A, Miralpeix M, Ramos I, et al (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther. Epub ahead of print.
- Ni, H; Soe, Z; Moe, S (Sep 19, 2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease.". The Cochrane database of systematic reviews 9: CD010509. PMID 25234126.
- "Almirall and Menarini sign a licence agreement and commercial alliance for Aclidinium in the majority of European member states and a number of non-EU countries" (Press release). Menarini. Retrieved 2012-03-26.
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|